Copyright
©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 28, 2007; 13(44): 5813-5821
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5813
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5813
Moving forward in colorectal cancer research, what proteomics has to tell
Nerea Bitarte, Eva Bandrés, Ruth Zárate, Natalia Ramirez, Jesus Garcia-Foncillas, Laboratory of Pharmacogenomics, Center for Medical Applied Research, Unit of Clinical Genetics, University Clinic, Department of Oncology and Radiotherapy, University Clinic, University of Navarra, Pamplona 31008, Spain
Author contributions: All authors contributed equally to the work.
Correspondence to: Jesús García-Foncillas, MD, PhD, Laboratory of Pharmacogenomics, Center for Medical Applied Research, Department of Oncology and Radiotherapy, University Clinic, University of Navarra, Avda Pio XII 36, Pamplona 31008, Spain. jgfoncillas@unav.es
Telephone: +34-948-194700-1008 Fax: +34-948-194718
Received: July 30, 2007
Revised: September 12, 2007
Accepted: October 17, 2007
Published online: November 28, 2007
Revised: September 12, 2007
Accepted: October 17, 2007
Published online: November 28, 2007
Abstract
Colorectal cancer is the third most common cancer and is highly fatal. During the last several years, research has been primarily based on the study of expression profiles using microarray technology. But now, investigators are putting into practice proteomic analyses of cancer tissues and cells to identify new diagnostic or therapeutic biomarkers for this cancer. Because the proteome reflects the state of a cell, tissue or organism more accurately, much is expected from proteomics to yield better tumor markers for disease diagnosis and therapy monitoring. This review summarizes the most relevant applications of proteomics the biomarker discovery for colorectal cancer.
Keywords: Proteomics, Colorectal cancer, Biomarker